Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03440047 · ClinicalTrials.gov registry record · NA
Minimal Risk Registry of Endoscopic Image and Pathology Correlation for Fujiflim
A NA study of Gastro-Intestinal Disorder, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 355
- Enrollment target
- 2
- Study locations
NCT03440047: Completed NA study of Gastro-Intestinal Disorder, sponsored by Mayo Clinic.
NCT03440047 is a NA study of Gastro-Intestinal Disorder that has completed, run by Mayo Clinic. The registered enrollment target is 355 participants, above the 134-participant average among 7 other Gastro-Intestinal Disorder trials with a reported enrollment target (165% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03440047, a NA study of Gastro-Intestinal Disorder, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 355 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to see if advanced endoscopic imaging may be helpful to accurately distinguish pathological tissue from normal tissue and guide therapy of endoscopically identified pathology.
Primary Outcome
Subjects presenting with gastrointestinal mucosal disorders will have a biopsy based on clinical standard of care. Just prior to the biopsy, a standard set of electronic images will be captured using the Fujifilm 7000 Blue Light Imaging System with 4-LED Multi Light Technology. Images will be correlated with the final clinical and histological diagnosis of the gastrointestinal disorder.
Conditions Studied
Interventions
- DEVICE Fuji Flim Processor VP-7000, Light Source BL-7000
Study Locations (2)
Florida
- Mayo Clinic in Florida - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2017-08-28 |
| Est. Completion | 2023-03-01 |
| Phase | NA |
What the finished NCT03440047 record still lists
NCT03440047 is an interventional study that assigns participants to a tested intervention. The registered 355 participants enrollment target is mid-sized for trials with a published cap, above the 134-participant average among 7 other Gastro-Intestinal Disorder trials with a reported enrollment target (165% higher).
The record links to 1 condition, with Gastro-Intestinal Disorder appearing as the primary indexed condition, and to 1 intervention - of which Fuji Flim Processor VP-7000, Light Source BL-7000 is the first listed.
NCT03440047 reports a single indexed study location in Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT03440047 about?
NCT03440047 is a clinical study titled "Minimal Risk Registry of Endoscopic Image and Pathology Correlation for Fujiflim". The purpose of this study is to see if advanced endoscopic imaging may be helpful to accurately distinguish pathological tissue from normal tissue and guide therapy of endoscopically identified pathology.
What is the current status of trial NCT03440047?
This trial is currently completed. It is a NA study. The enrollment target is 355 participants. The study started on 2017-08-28. Estimated completion is 2023-03-01.
What conditions does trial NCT03440047 study?
This clinical trial studies the following conditions: Gastro-Intestinal Disorder.
What interventions are being tested in trial NCT03440047?
The interventions under investigation include: Fuji Flim Processor VP-7000, Light Source BL-7000 (DEVICE).
Who is sponsoring clinical trial NCT03440047?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03440047 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastro-Intestinal Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gastroparesis Registry 4
RECRUITING
-
Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).
RECRUITING · Phase 1
-
MTT for Children With ASD Who Have Gastrointestinal Disorders
ACTIVE NOT RECRUITING · Phase 2
-
Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders
ACTIVE NOT RECRUITING · Phase 2
-
Biological Sample Repository for Gastrointestinal Disorders
ACTIVE NOT RECRUITING
-
The Gut-Brain Study
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07133308 · 355 participants · Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
- NCT07193511 · 355 participants · Phase 1
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
- NCT06077838 · 356 participants · NA
RELAXaHEAD for Headache Patients (Phase III)
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI